 LA JOLLA, Calif., Aug. 30, 2021 GLOBE NEWSWIRE -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market NASDAQ:MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced that an abstract regarding MediciNovas ongoing Phase 2b3 clinical trial of MN-166 ibudilast in amyotrophic lateral sclerosis ALS has been accepted for presentation at the 32nd International Symposium on ALSMND amyotrophic lateral sclerosismotor neurone disease to be held virtually on December 7 - 10, 2021. 